Antiviral drug discovery against SARS-CoV

Yu Shan Wu, Wen Hsing Lin, John T.A. Hsu, Hsing Pang Hsieh

研究成果: Review article同行評審

37 引文 斯高帕斯(Scopus)

摘要

Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV Mpro; 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.

原文English
頁(從 - 到)2003-2020
頁數18
期刊Current Medicinal Chemistry
13
發行號17
DOIs
出版狀態Published - 2006 七月

All Science Journal Classification (ASJC) codes

  • 生物化學
  • 分子醫學
  • 藥理
  • 藥物發現
  • 有機化學

指紋

深入研究「Antiviral drug discovery against SARS-CoV」主題。共同形成了獨特的指紋。

引用此